Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients

Cherie Severson

Abstract


A novel approach to treating cancer in the settings of Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) is the use of a subcutaneous (SC) injection of Rituximab (in addition to standard combination chemotherapy). Alberta cancer patients can safely benefit from the administration of subcutaneous Rituximab in numerous ways while still ensuring efficacy and optimal treatment for their cancer. Review of the American literature revealed several studies indicating the benefits of SC Rituximab. The Spark Thera trial revealed pharmacokinetic results of Rituximab concentrations in NHL patients who were administered a fixed dose of 1,400 mg (625mg/m2) SC achieved non-inferior Ctrough and AUC levels compared to those patients administered the standard IV dose of  375mg/m2. The SABRINA study results reveal an ORR 54% (IV+ chemo) versus 57% (SC + chemo); CR 19% versus 29% respectively and PR 35% versus 37% respectively with comparable safety profiles. The Sawyer B025341 Phase 1b study shows non-inferior pharmacokinetics and comparable safety profiles using a fixed dose of 1,600 mg of Rituximab SC compared to Rituximab 500mg/m2 IV in patients with CLL receiving combination (FC) chemotherapy. Further American studies report relative reductions in mean chair time, reduced pharmacy preparation time and increased ability to improve the number of other patients that can be treated increasing a facility’s overall efficiency by administering Rituximab SC versus Rituximab IV. The transition from IV to SC Rituximab is further supported by the application of a cost analysis. To date, SC Rituximab is non-inferior and has a comparable safety profile when compared to IV Rituximab. A SC injection of Rituximab could have many benefits for Alberta cancer patients while still ensuring efficacy and optimal treatment of their disease.

Key words: subcutaneous Rituximab, intravenous Rituximab, cost analysis, drug access


Full Text:

PDF

References


Alberta Health Services. (2013). Clinical practice guidelines: Lymphoma. Version 8: Author. Retrieved from http://www.albertahealthservices.ca

Assouline, S., Buccceri, V., Delmer, A., Doelken, G., Gaidano, G., MIntyre, C., Brewster, M., Hourcade-Potelleret, F., Sayyed, P., & Badoux, X. (2012). Subcutaneous Rituximab in combination with Fludarabine and Cyclophosphamide for patients with chronic lymphocytic leukemia. American Society of Hematology: Abstract: 1637.

Aue, G., Lindorfer, M.A., Beum, P.V., Pawluczkowycz, A.W., Vire, B., Hughes, T., Taylor, R.P., & Wiestner, A. (2010). Fractionated subcutaneous rituximab is well tolerated and preserves CD20 expression on tumour cells in patients with chronic lymphocytic leukemia. Haematologica, 95(2), 329–333.

BARD medical supplies. (2014). Vitality Medical. Retrieved from http://www.vitalitymedical.com

Baxter (2014). Baxter product catalogue. Retrieved from http://www.baxter.ca

Biogen Idec Inc. and Genentech Inc. (2006). Rituximab drug monograph. Retrieved from http://www.bloodjournalhematologylibrary.org

Canadian Partnership Against Cancer. (2014). Canadian cancer trials: Subcutaneous Rituximab. Retrieved from: http://www.canadiancancertrials.ca

Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Celigny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., & MacDonald, D. (2014). Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA) stage 1 analysis of a randomized phase 3 study. The Lancet Oncology, 15(3), 343–352.

Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Celigny, P., Barrett, M., Berge, C., … MacDonald, D. (2014). Stage 1 results of the phase III SABRINA study comparing subcutaneous versus intravenous administration of rituximab in combination with chemotherapy in patients with previously untreated follicular lymphoma. American Society of Hematology: Abstract 1629.

De Cock, E., Kritiou, P., Tao, S.,Weisner, C., Waterboer. T., & Carella., A.M. (2013a). Time and resource savings with rituximab subcutaneous injection versus rituximab intravenous infusion: First results from a time and motion study. New Evidence: EHA Congress Abstract: P507.

De Cock, E., Kritikou, P., Tao, S., Wiesner, C., Waterboer, T., & Carella, A.M. (2013b). Time savings with Rituximab subcutaneous injection versus intravenous infusion: Final analysis from a time-and-motion study in 8 different countries. Blood: Nov 15, 122(21), Abstract 1724.

Frost, G.I. (2007). Recombinant human hyaluronnidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opinion Drug Delivery, 4(4), 427–440.

Government of Alberta. (2014). Alberta learning information service: Occupational profile pharmacist. Retrieved from http://www.occinfo.alis.alberta.ca

Griffiths, R.I., Gleeson, M.L., Mikhael, J., & Danese, M.D. (2012). Impact on medical cost, cumulative survival and cost effectiveness of adding rituximab to first line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER medicare. Journal of Cancer Epidemiology, 1–13. doi:10.1155/2012/ID 978391

Hoffmann-LaRoche. (2014). A study of patient preferences with subcutaneous versus intravenous MabThera Rituximab in patients with CD20+ diffuse large b-cell lymphoma or CD20+ follicular non hodgkins lymphoma grades 1, 2, or 3a. National Institutes of Health: trial ID NCT01724021. Retrieved from: http://www.clinicaltrials.gov

Jagger, J., Hunt, E., & Pearson, R.D. (1990). Estimated cost of needle stick injuries for six major needle devices. Infection Control Hospital Epidemiology, Nov, 11(11), 584–588.

Mao, C.P., Brovarney, M.R., Dabbagh, K., Birnbock, H.F., Richter, W.F., & Del Nagro, C.J. (2013). Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. Public Library of Science, Nov, 8(11), 1–12.

Medical Technology Association of Australia. (2013). Value of technology: Needlestick and sharps injuries and safety-engineered medical devices. April, 1–19. Retrieved from http://www.mtaa.org.au

Roche. (2012). Roche reports positive studies of MabThera given by subcutaneous injection. Roche Group Media Relations. Media release: Dec, 1–4. Retrieved from http://www.roche.com

Salar, A., Avivi, I., Larouche, J.F., Janikova, A., Pereira, J., Brewster, M., Catalani, O., … Haynes, A. (2012). Final results of the BP22333 study demonstrate non inferior pharmacokinetics and safety of subcutaneous administration of rituximab compared with intravenous administration as maintenance therapy in patients with follicular lymphoma. American Society of Hematology. Abstract 1641.

The Gazette (Montreal). (2008, Aug 13). Equal access to cancer drugs a myth, report says. CanWest MediaWorks Publications Inc. Retrieved from http://www.canada.com

Turner & Associates. (2008). Issues of access to cancer drugs in Canada: A report for the Canadian Cancer Action Network. Toronto, Ontario: Author.

United Nurses of Alberta. (2013). Collective agreement nursing salaries online. Retrieved from http://www.una.ab.ca


Refbacks

  • There are currently no refbacks.


Bookmark and Share